323 results
Thumbnail

001503 - Urticaria exacerbations in children with chronic urticaria receiving COVID-19 vaccination

Thumbnail

001566 - Anaphylaxis to diethyltoluamide (DEET) containing insect repellent

Thumbnail

001589 - Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH)

Thumbnail

100093 - Arcoxia - cause of erythema fixed drug

Thumbnail

100541 - Systematic evaluation of ChatGPT`s performance on 40 dermatological allergology questions with clinical error impact assessment for erroneous AI-guided chatbot-advice

Thumbnail

D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Thumbnail

D1.128 - Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency

Thumbnail

D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD

Thumbnail

D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria

Thumbnail

D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series

Thumbnail

D1.376 - Emerging inmunomodulatory agents for atopic dermatitis

Thumbnail

D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report

Thumbnail

D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis

Thumbnail

D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis

Thumbnail

D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity

Thumbnail

D2.295 - Characterization of Treatment-Refractory Chronic Urticaria: A Large-Scale Retrospective Analysis of Clinical and Laboratory Parameters

Thumbnail

D2.296 - Allergic contact dermatitis caused by a oxybutynin in a transdermal patch

Thumbnail

D2.297 - SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Thumbnail

D2.299 - A novel synthetic molecule LN49 suppressed oxidative stress and inflammation in skin epithelial and fibroblast cells via activating Nrf-2 signaling pathway

Thumbnail

D2.300 - Fixed Drug Eruption related to the use of NSAIDs